Abstract
Objective: Procalcitonin (PCT) was originally described in 1984 as a 116-aminoacid protein with a molecular weight of 14,5 kDa. The PCT gene, referred to as Calc-1, is located on chromosome 11p15.4 and was sequenced in 1989. The promoter has sites for basal transcription factors but more interestingly, also has sites for NF|[kappa]||[beta]| (Nuclear factor |[kappa]||[beta]|) and AP-1(Activator protein-1), factors induced under inflammatory conditions. Type II diabetes mellitus is associated with oxidative stress and elevation of advanced glycation end products (AGEs). AGEs are produced by a non-enzymatic, Maillard reaction between reducing sugars and either proteins or lipids. AGE's interacts the receptor for advanced glycation end products (RAGE) and, RAGE activation is caused by elevation of transcriptional factors NF|[kappa]||[beta]| and AP-1. These factors induce procalcitonin gene expression. The aim of this study was to determine whether or not procalcitonin is a specific marker in patients with type II DM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
